MedTrace Logo

Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors

NCT00488644 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-06-24

Study results available
· View outcomes & findings →

Summary

Primary Objectives:

1. Assess whether combined treatment with Levothyroxine and Liothyronine improves learning and memory.
2. Explore the relationship between T3 treatment and other domains of cognitive function, quality of life, and mood.

Conditions

Interventions

DRUG

Levothyroxine

75 mcg by mouth (PO) Daily for 8 Weeks

DRUG

Liothyronine

15 mcg PO Daily for 8 Weeks

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Victor Levin, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00488644 on ClinicalTrials.gov